Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy

Authors

  • Alison Grann M.D.,

    1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Paul B. Gaudin M.D.,

    1. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Adam Raben M.D.,

    1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Kent Wallner M.D.

    Corresponding author
    1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Radiation Oncology (174), Puget Sound Health Care System, Department of Veterans Affairs, 1660 S. Columbian Way (174), Seattle, Washington 98108-1597
    Search for more papers by this author

Abstract

To evaluate the role of detailed pathologic features in predicting outcome for early-stage prostate cancer treated with I-125 brachytherapy. The pretreatment biopsy slides of 103 patients with T1/T2 and Gleason scores of 4–7 prostatic carcinoma, which was treated by transperineal I-125 implantation, were reviewed retrospectively by a single pathologist (P.B.G.). Biochemical tumor control rates [prostate-specific antigen (PSA) below 1.0] were correlated with pretreatment PSA, Gleason score, the amount of tumor in the biopsy samples, and the presence of perineural invasion.In Cox proportional-hazard, multivariate analysis, the strongest predictors of failure were pretreatment PSA above 10 ng/ml (P = 0.013) and the length of the biopsy specimen replaced by tumor (P = 0.15). The percent of biopsy tissue replaced by tumor (P = 0. 74), perineural invasion (P = 0.78), and Gleason score (P = 0.66) were less predictive of prognosis. It was concluded that pretreatment PSA is the strongest predictor of biochemical failure. Detailed assessment of pathological features on needle biopsy added little prognostic information beyond that of pretreatment PSA alone. Like all other prognostic parameters for prostate cancer, there is considerable overlap in pathologic features between those patients who will or will not be controlled biochemically. Radiat. Oncol. Invest. 6:170–174, 1998. © 1998 Wiley-Liss, Inc.

Ancillary